Global Search | Novartis

Hide Filters

Sort by

Relevance

Newest first

Oldest first

Showing 2664 results

Media Release / Sep 22, 2018
New analysis of Novartis Phase III brolucizumab (RTH258) data reinforces superior reduction of retinal fluid, a key marker of disease activity in nAMD
Pre-specified analysis provides insight into maintenance treatment effectiveness with like-for-like comparison of brolucizumab versus aflibercept over entire week 36 to 48 treatment period …
Media Release / Sep 24, 2018
Novartis announces five grant recipients of eXcellence in Ophthalmology Vision Award (XOVA) for nonprofit sustainable eye health initiatives
A panel of independent ophthalmologists and optometrists selected five winners out of more than 100 entries from 34 countries The 2018 grants support initiatives ranging from training teachers…
Media Release / Sep 22, 2018
Novartis to file for new Lucentis® (ranibizumab) indication in retinopathy of prematurity (ROP), a rare disease in premature infants that often leads to blindness
In the Phase III RAINBOW study, despite marginally missing statistical significance for the primary endpoint of demonstrating superiority of Lucentis® to laser surgery, Lucentis was shown to be…
Media Release / Oct 04, 2018
Sandoz Healthcare Access Challenge (HACk) returns, seeking digital solutions to local healthcare access challenges
Despite major advances in modern medicine, universal access to healthcare remains the largest unmet medical need Building on the inaugural Sandoz HACk, this year's competition expands to seek…
Media Release / Oct 03, 2018
Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals
Clinical and pre-clinical stage programs focused on addressing growing need for new treatments against drug resistant Gram-negative bacteria Agreement is part of Novartis strategy to…
Media Release / Oct 09, 2018
Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study
Data published in the American Journal of Hematology show more than twice as many patients taking crizanlizumab did not experience a disease-related pain crisis (also called vaso-occlusive crisis, or…
Media Release / Oct 08, 2018
Novartis announces FDA and EMA filing acceptance of siponimod, the first and only drug shown to meaningfully delay disability progression in typical SPMS patients
There is a critical need for safe and effective treatments for secondary progressive multiple sclerosis (SPMS) - a highly debilitating form of MS characterized by gradual, irreversible worsening of…
Media Release / Oct 10, 2018
Breadth of data at ECTRIMS underpins Novartis' relentless commitment to decoding the science of multiple sclerosis (MS) and decreasing the patient burden
33 abstracts from the leading MS portfolio include data for Gilenya® (fingolimod), and investigational drugs siponimod (BAF312) and ofatumumab (OMB157) New research will be presented on…
Media Release / Oct 11, 2018
Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access
Global resolution secures patient access to Sandoz biosimilar Hyrimoz® (adalimumab)[1] for the reference medicine Humira®** Resolution paves way for 2018 launch in key European markets and…
Media Release / Oct 10, 2018
Novartis announces new data from the first direct head-to-head trial to demonstrate superior efficacy of Gilenya® over Copaxone® in patients with relapsing remitting multiple sclerosis
Topline findings from ASSESS show adult relapsing remitting multiple sclerosis (RRMS) patients taking Gilenya (fingolimod) 0.5mg experienced significantly fewer relapses than patients on Copaxone (…